SCHEMBL25219240

SCHEMBL25219240

N=S(=O)(c1ccc(C(=O)Nc2cc(-c3ccc(F)cc3)ccc2N)cc1)C1CC1

nearest known ligand 0.61

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ HDAC2 Q92769 17/20 0.61
▸ HDAC1 Q13547 15/20 0.54
▸ HDAC3 O15379 15/20 0.54
▸ CHEK1 O14757 1/20 0.48
▸ NTRK1 P04629 1/20 0.48
▸ MET P08581 1/20 0.48
▸ PIM1 P11309 1/20 0.48
▸ LTK P29376 1/20 0.48
▸ GRK5 P34947 1/20 0.48
▸ MAP2K2 P36507 1/20 0.48
▸ CDK8 P49336 1/20 0.48
▸ NEK2 P51955 1/20 0.48
▸ LIMK1 P53667 1/20 0.48
▸ TYRO3 Q06418 1/20 0.48
▸ MAP4K2 Q12851 1/20 0.48
▸ DYRK1A Q13627 1/20 0.48
▸ AURKB Q96GD4 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25244474 1.00 HDAC2 (0.61) HDAC2HDAC1HDAC3CHEK1NTRK1
SCHEMBL25216647 1.00 HDAC2 (0.61) HDAC2HDAC1HDAC3CHEK1NTRK1
SCHEMBL30474676 1.00 HDAC2 (0.61) HDAC2HDAC1HDAC3CHEK1NTRK1
SCHEMBL31108956 0.89 HDAC2 (0.67) HDAC2HDAC1HDAC3CHEK1NTRK1
SCHEMBL25270031 0.89 HDAC2 (0.47) HDAC2HDAC1HDAC3CHEK1NTRK1
SCHEMBL25251026 0.87 HDAC2 (0.69) HDAC2HDAC1HDAC3
SCHEMBL25219035 0.86 HDAC2 (0.44) HDAC2HDAC1HDAC3
SCHEMBL25219052 0.86 HDAC2 (0.44) HDAC2HDAC1HDAC3
SCHEMBL25214192 0.86 HDAC2 (0.44) HDAC2HDAC1HDAC3
SCHEMBL30474776 0.86 HDAC2 (0.44) HDAC2HDAC1HDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250136570-A1 HDAC INHIBITORS AND THERAPEUTIC USE THEREOF TANGO THERAPEUTICS, INC. 2025-05-01 — — US disclosed
EP-4441033-A1 NOVEL HDAC INHIBITORS AND THERAPEUTIC USE THEREOF Tango Therapeutics, Inc. (US) 2024-10-09 — — EP disclosed
US-12043607-B2 HDAC inhibitors and therapeutic use thereof TANGO THERAPEUTICS, INC. (US) 2024-07-23 — — US disclosed
US-12043607-B2 HDAC inhibitors and therapeutic use thereof TANGO THERAPEUTICS, INC. (US) 2024-07-23 — — US disclosed
US-12043607-B2 HDAC inhibitors and therapeutic use thereof TANGO THERAPEUTICS, INC. (US) 2024-07-23 — — US disclosed
WO-2023102162-A1 TGONOVEL HDAC INHIBITORS AND THERAPEUTIC USE THEREOF TANGO THERAPEUTICS, INC. (US) 2023-06-08 — — WO disclosed
WO-2023102162-A1 TGONOVEL HDAC INHIBITORS AND THERAPEUTIC USE THEREOF TANGO THERAPEUTICS, INC. (US) 2023-06-08 — — WO disclosed
US-20230174501-A1 NOVEL HDAC INHIBITORS AND THERAPEUTIC USE THEREOF TANGO THERAPEUTICS, INC. 2023-06-08 — — US disclosed
US-20230174501-A1 NOVEL HDAC INHIBITORS AND THERAPEUTIC USE THEREOF TANGO THERAPEUTICS, INC. 2023-06-08 — — US disclosed
US-20230174501-A1 NOVEL HDAC INHIBITORS AND THERAPEUTIC USE THEREOF TANGO THERAPEUTICS, INC. 2023-06-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230174501-A1 NOVEL HDAC INHIBITORS AND THERAPEUTIC USE THEREOF HDAC1, HDAC7, HDAC5 HDAC2 9/4885HDAC1 1/4885HDAC3 8/4885
US-20250136570-A1 HDAC INHIBITORS AND THERAPEUTIC USE THEREOF HDAC1, HDAC7, HDAC5 HDAC2 8/4885HDAC1 1/4885HDAC3 9/4885
US-12043607-B2 HDAC inhibitors and therapeutic use thereof HDAC1, HDAC7, HDAC5 HDAC2 8/4885HDAC1 1/4885HDAC3 9/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback